Industry News
Pharmaceutical Industry News
The FDA’s Pharmacy Compounding…
The FDA’s Pharmacy Compounding Advisory Committee will convene this summer to discuss seven peptides that are currently restricted from use in compounded medications.
With Daiichi Sankyo’s priorities…
With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in particular—the Tokyo-based drugmaker is following in the footsteps of several of its peers with a deal to split from its consumer
Innovative treatment options like…
Innovative treatment options like targeted therapy and advanced molecular diagnostic techniques are opening new doors for patients.
Before committing to research, AI…
Before committing to research, AI is helping pharma teams identify which concepts are most likely to resonate with their key customers
The company and its global…
The company and its global distrubution partner the Global Fund expanded its commitment to bring Yeztugo to 3 million people worldwide by 2028, but Doctors Without Borders (MSF) says supply is still "not nearly enough."
AI heavyweight Anthropic has…
AI heavyweight Anthropic has appointed Novartis CEO Vas Narasimhan to its board of directors as the link between the pharmaceutical industry and Silicon Valley deepens.
For Astellas’ chief…
For Astellas’ chief manufacturing officer, Rao Mantri, Ph.D., production is not just about a reliable supply of a pharmaceutical product. Manufacturing serves as a crucial bridge that helps link promising research to patients in the
Lucy Liu has joined Pfizer’s…
Lucy Liu has joined Pfizer’s mission to deliver a knockout blow against cancer, becoming the latest face of the Big Pharma’s campaign encouraging people to get screened.
Just two months after the FDA…
Just two months after the FDA accepted for review Teva’s long-acting version of a decades-old schizophrenia drug, the Israeli pharma is launching a community project to help people with the disorder and their carers.
Drug names are complicated things….
Drug names are complicated things. For one, they must linguistically fulfill the role of being a shiny bauble for prescribers to be memorable enough to outshine competitors. But there’s much more than just surface-level appeal
Travere is eyeing a collective $3…
Travere is eyeing a collective $3 billion U.S. opportunity for Filspari thanks to a new rare kidney disease nod, plus the med's initial 2023 approval in another rare kidney indication.
Even as Eli Lilly gets underway…
Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, the FDA's approval letter for the oral treatment shows lingering reservations about multiple "unexpected serious" risks potentially related to the drug.
Axplora leaders share how CDMO…
Axplora leaders share how CDMO partnerships accelerate complex drug development and speed therapies to patients.
A prominent physician voice in the…
A prominent physician voice in the House of Representatives has introduced a new bill that would compel insurers to apply the cost for drugs purchased from direct-to-consumer platforms to deductibles and out-of-pocket maximums.
Protagonist Therapeutics-partnered…
Protagonist Therapeutics-partnered Icotyde has the potential to become one of Johnson & Johnson's "largest products ever," CEO Joaquin Duato said on the company's first-quarter earnings conference call.
The AI will be used to analyze…
The AI will be used to analyze complex datasets and shrink R&D timelines, Novo said. It'll additionally use the tech to seek efficiencies across manufacturing and corporate functions.
The FDA has scolded Pfizer over…
The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately communicate the indication, contraindications and risks.
F.D.A. Calls on Drug Developers to Publish Missing Data from Thousands of Trials
Many unfavorable results go unreported, skewing the available data on medical treatments.
The era of off-label guesswork for…
The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 victory for Roche’s Enspryng suggests a first-of-its-kind FDA approval may not be far
Eli Lilly has chalked up another…
Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer, this time as an industry first.